Seagen Inc (Seagen), formerly Seattle Genetics Inc, develops and commercializes monoclonal antibody-based drugs for the treatment of cancer. The company operates through a single reportable segment, which focuses on the development and sale of pharmaceutical products on its behalf or in collaboration with other companies.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Seagen conducts R&D to develop its product candidates and antibody-based technologies. The company is investigating Adcetris in Phase II clinical trials as a combination therapy along with nivolumab for relapsed Hodgkin lymphoma in children; and as a monotherapy for relapsed Hodgkin lymphoma (HL) or Peripheral T-cell lymphoma (PTCL); and PTCL or frontline Hodgkin lymphoma in patients who failed to respond to chemotherapy. It is also advancing Phase II clinical investigation of a combination therapy of Adcetris with nivolumab, doxorubicin, and dacarbazine for Hodgkin lymphoma. The company is developing Echelon-3 in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma. Its Phase II clinical trials also include with combination of retreatment, monotherapy, checkmate 744, nivolumab and cyclophosphamide, doxorubicin, and prednisone and pembrolizumab post pd-1 for the treatment of HL, metastatic solid tumors, and PTCL. The company is advancing the development of Padcev candidates EV-302, EV-303, EV-304, EV-103, EV-104, and EV-202 in collaboration with Astellas. Seagen is investigating EV-302 in Phase III clinical trials as a combination therapy with pembrolizumab with or without platinum agents for frontline metastatic urothelial cancer. It is also evaluating EV-103 in Phase II clinical trials in combination with platinum agents and pembrolizumab for muscle invasive bladder cancer or frontline metastatic urothelial cancer; EV-104 in Phase I trial for dacarbazine; and EV-202 in Phase II clinical studies as a monotherapy for metastatic solid tumors of head and neck, gastric/esophagus, and breast cancer and non-small cell lung cancer. The company developing EV-303 and EV-304 in combination with pembrolizumab is in Phase III clinical trials for the treatment of Perioperative muscle invasive bladder cancer. Seagen is investigating Tukysa candidates: HER2CLIMB-02 in Phase III as a combination therapy with ado-trastuzumab (T-DM1) for HER2+ metastatic breast cancer in patients who were previously treated with a trastuzumab and taxane; and MOUNTAINEER in Phase III clinical studies as a combination therapy with trastuzumab for HER2+ metastatic colorectal cancer and HER2CLIMB-05 is in Phase III as a combination therapy with trastuzumab and pertuzumab for HER2+ metastatic breast cancer. Other Tukysa pipeline candidates for various indications include COMPASSHER2 RD, in combination with T-DM1; COMPASSHER2 RD, in combination with T-DM1; MOUNTAINEER-02, in combination trastuzumab, ramucirumab and chemotherapy; tucatinib in combination with trastuzumab with or without fulvestrant; and tucatinib in combination with trastuzumab and oxaliplatin. The company’s TUC-019 in combination with trastuzumab is in Phase II clinical trials for the treatment of metastatic solid tumors her2 alterations. The company is advancing Tivdak candidates: innovaTV 205; innovaTV 207, and innovaTV 301 in collaboration with Genmab. It is advancing innovaTV 205 in Phase I/II clinical studies as a combination therapy other cancer agent for the treatment of first- and second-line metastatic cervical cancer; innovaTV 207 in Phase II clinical studies as a monotherapy for relapsed, locally advanced or metastatic solid tumors; and innovaTV 301 in Phase III clinical studies as a monotherapy for metastatic/recurrent cervical cancer. The company is also investigating ladiratuzumab vedotin in Phase II for breast cancer and solid tumors; disitamab vedotin in phase II for HER2-expressing metastatic urothelial cancer; and SGN-ALPV, SGN-BB228, SGN-B7H4V, SEA-CD70 and SEA-TGT are in phase I for the treatment of Solid tumors and lymphoma. In FY2022, the company spent US$1,344.4 million on R&D, which as a percentage of revenue stood at 68.5%.